New hope for myelofibrosis: experimental combo targets Drug-Resistant patients

NCT ID NCT06887803

Recruiting now Disease control Sponsor: iOnctura Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether adding roginolisib to the standard drug ruxolitinib is safe and tolerable for adults with myelofibrosis whose disease no longer responds to JAK inhibitors. The study will enroll 26 participants and monitor side effects, heart changes, and lab results. If successful, this combination could become a new option for patients who have run out of effective treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: roginolisib (a PI3Kδ inhibitor) combined with ruxolitinib (a JAK inhibitor)
What this could lead to: If this combination proves safe and effective, it could offer a new treatment option for myelofibrosis patients who have stopped responding to standard JAK inhibitor therapy.
What could go wrong: This is an early-phase trial with only 26 participants, so results may not apply to all patients. The combination may cause unexpected side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS，MF are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS，MF

Contacts and locations

Locations

Avigunda Gran via de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat
RECRUITING

Barcelona, 08908, Spain
Azienda Ospedaliero Universitaria Careggi Firenze, Struttura Complessa di Ematologia
RECRUITING

Florence, Florence, 50134, Italy
Azienda Sanitario Universitaria Friuli Centrale
RECRUITING

Udine, 33100, Italy
Belfast City Hospital
RECRUITING

Belfast, BT9&AB, United Kingdom
Guy´s and St. Thomas NHS Foundation Trust
NOT_YET_RECRUITING

London, SE1 9RT, United Kingdom
Hospital Universitario de Salamanca
RECRUITING

Salamanca, 37007, Spain
IRCCS Clinical Institute Humanitas
RECRUITING

Rozzano, Milan, 20089, Italy
Istituto Romagnolo per lo Studio dei Tumori
RECRUITING

Meldola, 47014, Italy
Istituto di Ematolgia e Oncologia Medica
RECRUITING

Bologna, 40138, Italy
START Madrid CIOCC
RECRUITING

Madrid, 28050, Spain
United Lincolnshire Teach Hospitals NHS Trust, Pilgrim Hospital Boston
RECRUITING

Boston, Lincolnshire, PE21 9QS, United Kingdom
Vall d'Hebron University Hospital
RECRUITING

Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.